Coronavirus Scientific Resources

Resources to educate and collaborate on COVID-19 responses

In confronting this crisis, we believe that science will win. Be sure to keep up with all of our important updates surrounding COVID-19, including press releases, supply updates and more.

COVID-19 Featured Publication

Featured Coronavirus Publication

Two Phase 1/2 umbrella trials in Germany and the US investigate several LNP-encapsulated RNA 60 vaccine candidates developed in `Project Lightspeed

Two Phase 1/2 umbrella trials in Germany and the US investigate several LNP-encapsulated RNA 60 vaccine candidates developed in `Project Lightspeed`. Recently, we have reported interim data obtained in the US trial (NCT04368728) for the most advanced candidate BNT162b1. This study now complements our previous report with available data from the German trial 75 (NCT04380701, EudraCT: 2020-001038-36), providing a detailed characterization of antibody and T76 cell immune responses elicited by BNT162b1 vaccination.

Read this publication

APPLYING OUR SCIENTIFIC EFFORTS TO ADDRESS THE EPIDEMIC

Antiviral Efforts -
Advancing our protease inhibitors:

Vaccine Efforts -
Potentially preventing infections using mRNA vaccines:

Anti-infective Efforts -
Sharing azithromycin data:

In an effort to share information that could benefit COVID-19 mitigation efforts, Pfizer researchers published a review in Clinical Pharmacology and Therapeutics which assesses published in vitro and clinical data regarding azithromycin as an agent with antiviral properties. This open access review may serve to facilitate the use of azithromycin in future research on COVID-19. Azithromycin is not approved for the treatment of viral infections.

Research that may inform future vaccination guidelines

Pfizer Inc. and the Liverpool School of Tropical Medicine’s Respiratory Infection Clinical Research Group launched two new studies to provide insights on the interaction between S. pneumoniae and SARS-CoV-2. Pfizer's collaboration agreement with Liverpool provides funding and in-kind laboratory testing support for this research.

Collaborating to address COVID-19

As outlined in Pfizer’s five-point plan, the company has been collaborating across the healthcare innovation ecosystem ranging from large pharmaceutical companies to the smallest of biotech companies, from government agencies to academic institutions to address the COVID-19 global health care crisis.

If you’re a researcher interested in collaborating,?contact [email protected]

Existing collaborations: